Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LF-PB for prevention of seroma after axillary lymph node dissection in breast cancer
2014-005289-31Phase 2Completed
- Sponsor
- Chemi S.p.A.
- Start
- Jan 2020
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in breast cancer comparing LF-PB 30 mg with Placebo (2 arms). Primary endpoint: Incidence of seromas requiring aspiration by day 28. Started Jan 2020; status: completed.
02
Drugs
octreotide
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2014-005289-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005289-31.